Clinical trial · Observational
A Study for PRO of CML in Real Word
Validation Value of the Questionnaire to Assess Health-related Quality of Life in Patients With CML
NCT05092048CI-TRIAL-00054628Case-OnlyunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CML (Chronic Myelogenous Leukemia) | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CML patient
- description
- ≥18 years old CML patiente
- interventionNames
- Other: questionnaire
Primary outcomes (1)
- measure
- Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia
- timeFrame
- 1 year
- description
- Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility record
- sex
- ALL
- stdAges
- ADULT
- OLDER_ADULT
- criteria
- null
- maximumAge
- null
- minimumAge
- 18 Years
- healthyVolunteers
- false
References
Publications (1)
- DERIVEDChen H, Wen Y, Zeng Y, Lin L, Sun B, Zhu H, He H, Wang X, Zou W, Zheng C, Zheng L, Huang J, Pang L, Huang J, Zhang Y, Lin H, Liu Z, Zhu W, Wang Q, Zhou X, Liu X, Qu H, Liu Z, Du X, Xu N. Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors. Oncol Ther. 2024 Mar;12(1):131-145. doi: 10.1007/s40487-023-00255-2. Epub 2023 Dec 16. PMID 38104036